Immunotherapy's cancer remit widens

Nature. 2013 May 30;497(7451):544. doi: 10.1038/497544a.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Agents / economics
  • Antineoplastic Agents / supply & distribution
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials as Topic
  • Combined Modality Therapy / statistics & numerical data
  • Drug Therapy, Combination / statistics & numerical data*
  • Humans
  • Immunotherapy / statistics & numerical data*
  • Ipilimumab
  • Neoplasms / drug therapy
  • Neoplasms / immunology*
  • Neoplasms / radiotherapy
  • Neoplasms / therapy*
  • Nivolumab

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Ipilimumab
  • Nivolumab